Develops single-use endoscopes for various medical procedures. Produces visualization devices for bronchoscopy, cystoscopy, and rhinolaryngoscopy. Now — the numbers.
This is an established company with proven profits.
Average growth of 9% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $49.6M would still be left in the vault — a solid cushion for hard times.
The market pays 32.8× for every dollar this company earns in a year — a price that already assumes things go well.
No analyst target is on record for this company.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
An investor who bought at the very peak is down 63% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 9% a year on average.
There is $134.7M in the vault; even if every debt were paid off, $49.6M would remain.
It pays out $0.06 per share each year — regular cash for whoever holds the stock.
The company’s market value is 33 times its annual profit. Even a small disappointment could hit the price hard.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.